A contemporary approach to thrombolytic therapy for pulmonary embolism

Abstract

Successfully utilized contemporary pulmonary embolism thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from pulmonary embolism and reduce morbidity from chronic pulmonary hypertension. Unlike myocardial infarction thrombolysis, a 2-week `time window' is available, during which treatment can be initiated. A high concentration of the thrombolytic agent is administered in a brief infusion lasting several hours. No special laboratory testing is needed. Currently, the only contemporary thrombolytic regimen for pulmonary embolism that is approved by the Food and Drug Administration is tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for pulmonary embolism include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and will focus on relevant endpoints such as the reduction of mortality and recurrent venous thromboembolism.

Keywords

anticoagulation pulmonary embolism thrombolysis thrombosis

References

Goldhaber SZ , Visani L , de Rosa M , for ICOPER . Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.

Jerjes-Sanchez C , Ramirez-Rivera A , Garcia M de L et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thrombos Thrombol 1995; 2: 227-229.

Cannon CP , Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism in patients. Am J Cardiol 1996; 78: 1149-1151.

Kasper W , Konstantinides S , Geibel A , Tiode N , Krause T , Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349.

Ribeiro A , Lindmarker P , Juhlin-Dannfelt A , Johnsson H , Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as predictor of mortality. Am Heart J 1997; 134: 479-487.

Lualdi JC , Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995; 130: 1276-1282.

Carson JL , Kelley MA , Duff A et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.

Kasper W , Konstantinides S , Geibel A et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.

Konstantinides S , Geibel A , Olschewski M et al. Impact of thrombolytic treatment on the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a Multicenter Registry. Circulation 1997; 96: 882-888.

10.

The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation 1973; 47: II-1-II-108.

11.

Urokinase-Streptokinase Embolism Trial. Phase 2 results. A cooperative study. JAMA 1974; 229: 1606-1613.

12.

Sharma GVRK , Burleson VA , Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842-845.

13.

Sharma GVRK , Folland ED , McIntyre KM , Sasahara AA. Longterm hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease. J Am Coll Cardiol 1990; 15: 65A-65A (abstr).

14.

Dalla-Volta S , Palla A , Santolicandro A et al. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 1992; 20: 520-526.

15.

Meyer G , Sors H , Charbonnier B et al on behalf of the European Cooperative Study Group for Pulmonary Embolism . Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992; 19: 239-245.

16.

Goldhaber SZ , Kessler CM , Heit JA et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.

17.

Goldhaber SZ , Haire WD , Feldstein ML et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.

18.

Goldhaber SZ , Nass N , McConnell MV , Chyu S , Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol 1999; 83: 804-806.

19.

Kanter DS , Mikkola KM , Patel SR , Parker JA , Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.

20.

PIOPED Investigators . Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263: 2753-2759.

21.

Stein PD , Hull RD , Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med 1994; 121: 313-317.

22.

Parker JA , Drum DE , Feldstein ML , Goldhaber SZ. Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med 1995; 36: 364-368.

23.

Daniels LB , Parker JA , Patel SR , Grodstein F , Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-188.

24.

Mikkola KM , Patel SR , Parker JA , Grodstein F , Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.

25.

Goldhaber SZ , Vaughan DE , Markis JE et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; ii: 886-889.

26.

Goldhaber SZ , Kessler CM , Heit J et al. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; ii: 293-298.

27.

Goldhaber SZ , Agnelli G , Levine MN , on behalf of the Bolus Alteplase Pulmonary Embolism Group . Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest 1994; 106: 718-724.

28.

Patel SR , Parker JA , Grodstein F , Goldhaber SZ. Similarity in presentation and response to thrombolysis among women and men with pulmonary embolism. J Thrombos Thrombol 1998; 5: 95-100.

29.

Mikkola KM , Patel SR , Parker JA , Grodstein F , Goldhaber SZ. Attenuation over 24 hours of the efficacy of pulmonary embolism thrombolysis among cancer patients. Am Heart J 1997; 134: 603-607.

30.

Verstraete M , Miller GAH , Bounameaux H et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-360.

31.

Sane DC , Califf RM , Topol EJ , Stump DC , Mark DB , Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111: 1010-1022.

32.

Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995; 107: 45S-51S.

33.

Pacouret G , Barnes SJ , Hopkins G , Charbonnier B. Rapid haemodynamic improvement following saruplase in recent massive pulmonary embolism. Thromb Haemost 1998; 79: 264-267.

34.

Tebbe U , Graf A , Kamke W et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in a massive pulmonary embolism. Am Heart J 1999; 138: 39-44.

35.

Delcroix M , Verhaeghe R , Mortelmans L et al. Recombinant staphylokinase thrombolysis in patients with acute pulmonary embolism. Am J Respir Crit Care Med 1998; 157: A768-A768.

36.

Goldhaber SZ. Pulmonary embolism thrombolysis. Broadening the paradigm for its administration. Circulation 1997; 96: 716-718.

37.

Ullmann M , Hemmer W , Hannekum A. The urgent pulmonary embolectomy: mechanical resuscitation in the operating theatre determines the outcome. Thorac Cardiovasc Surg 1999; 47: 5-8.

38.

Goldhaber SZ. Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. Chest 1998; 114: 1237-1238.

39.

Schmitz-Rode T , Janssens U , Schild HH , Basche S , Hanrath P , Günther RW. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest 1998; 114: 1427-1436.

40.

Koning R , Cribier A , Gerber L et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation 1997; 96: 2498-2500.